AstraZeneca (AZN) Financials

$66.29 +1.42 (+2.19%)

Closing price 04/11/2025 04:00 PM Eastern

Extended Trading

$66.63 +0.34 (+0.51%)

As of 04/11/2025 07:49 PM Eastern

Annual Income Statements for AstraZeneca

This table shows AstraZeneca's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	12,366	12,887	12,887	3,985	2,058	11,632	-167	9,261	17,086	18,113
Consolidated Net Income / (Loss)	12,365	13,074	13,153	4,196	1,227	11,736	-173	9,254	17,074	18,102
Net Income / (Loss) Continuing Operations	12,365	13,074	13,153	4,196	141	11,736	-173	9,254	17,074	18,102
Total Pre-Tax Income	12,640	13,220	12,512	4,196	1,548	11,736	-265	9,254	17,074	18,102
Total Operating Income	12,531	14,797	12,285	6,697	2,924	12,489	1,961	10,611	18,674	19,821
Total Gross Profit	20,062	18,876	18,147	17,154	19,463	21,318	24,980	31,960	37,543	43,866
Total Revenue	27,579	26,568	25,579	25,537	24,384	33,932	37,919	50,184	56,432	63,940
Operating Revenue	27,579	26,568	25,579	25,537	-	33,932	37,919	50,184	56,432	63,940
Total Cost of Revenue	-1,219	-2,798	-719	5,321	4,921	5,698	12,889	12,927	8,807	10,762
Operating Cost of Revenue	-1,219	-2,798	-719	5,321	4,921	5,698	12,889	12,927	8,807	10,762
Total Operating Expenses	16,267	14,569	14,013	13,519	17,741	15,745	23,019	26,646	28,951	33,357
Selling, General & Admin Expense	11,112	9,413	10,233	10,077	11,682	11,462	14,608	17,301	19,622	19,897
Research & Development Expense	5,997	5,890	5,757	5,932	6,059	5,991	9,736	9,762	10,935	13,583
Other Operating Expenses / (Income)	-842	-734	-1,977	-2,490	-	-1,708	-1,325	-417	-1,606	-123
Total Other Income / (Expense), net	109	-1,577	227	-2,501	-1,260	-753	-2,134	-1,357	-1,600	-1,719
Other Income / (Expense), net	108	-1,578	226	-2,509	-	-753	-2,134	-1,357	-1,600	-1,719
Net Income / (Loss) Attributable to Noncontrolling Interest	-1.00	187	266	211	-108	104	-6.00	-7.00	-12	-11
Basic Earnings per Share	$2.23	$2.77	$2.37	$1.70	$1.03	$2.44	-	$2.12	$3.84	$4.54
Weighted Average Basic Shares Outstanding	1.26B	1.27B	1.27B	1.27B	1.30B	1.31B	1.42B	1.55B	1.55B	1.55B
Diluted Earnings per Share	$2.23	$2.76	$2.37	$1.70	$1.03	$2.44	-	$2.11	$3.81	$4.50
Weighted Average Diluted Shares Outstanding	1.27B	1.27B	1.27B	1.27B	1.30B	1.31B	2.85B	1.56B	1.56B	1.56B
Weighted Average Basic & Diluted Shares Outstanding	-	-	1.27B	1.27B	1.30B	1.31B	1.42B	1.55B	1.55B	1.55B

No quarterly income statements for AstraZeneca are available.

This table details how cash moves in and out of AstraZeneca's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	4,280	-1,148	-1,686	1,537	547	5,208	20,121	13,786	10,520	20,354
Net Cash From Operating Activities	5,164	4,145	3,578	7,939	2,969	6,817	11,175	15,057	15,462	18,501
Net Cash From Continuing Operating Activities	5,164	4,588	1,536	7,939	-128	6,817	11,175	15,057	15,462	18,501
Net Income / (Loss) Continuing Operations	0.00	3,552	2,227	0.00	1,548	0.00	0.00	0.00	0.00	0.00
Depreciation Expense	2,852	-	-	-	-	3,149	6,530	5,480	5,387	6,688
Non-Cash Adjustments To Reconcile Net Income	2,312	181	926	8,476	-1,772	3,668	4,645	9,577	10,075	11,813
Net Cash From Investing Activities	0.00	-3,969	-2,328	-626	657	0.00	776	0.00	0.00	13
Net Cash From Continuing Investing Activities	0.00	-3,663	-1,894	-626	-98	0.00	776	0.00	0.00	13
Purchase of Investments	-	-1,098	-96	405	-1,494	-	776	0.00	-	13
Net Cash From Financing Activities	-884	-1,324	-2,936	-4,982	1,765	-1,609	8,170	-1,271	-4,942	1,840
Net Cash From Continuing Financing Activities	-884	-1,326	-2,916	-4,982	-737	-1,609	8,170	-1,271	-4,942	1,840
Repayment of Debt	-884	0.00	-1,764	-1,400	-1,686	-1,609	-4,759	-1,271	-4,942	-4,652
Issuance of Debt	-	2,491	1,988	-98	500	-	12,929	-	-	6,492
Cash Interest Received	123	-	-	193	-	47	34	60	287	343

No quarterly cash flow statements for AstraZeneca are available.

This table presents AstraZeneca's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	60,056	62,526	63,354	60,651	61,377	66,729	105,363	96,483	101,119	104,035
Total Current Assets	16,007	13,262	13,150	15,591	15,563	19,544	26,244	22,593	25,054	25,827
Cash & Equivalents	6,240	5,018	3,324	4,831	5,369	7,832	6,329	6,166	5,840	5,488
Short-Term Investments	615	911	1,258	1,107	885	302	152	326	238	220
Accounts Receivable	6,622	4,573	5,009	5,574	5,761	7,022	9,644	10,521	12,126	12,972
Inventories, net	2,143	2,334	3,035	3,872	3,263	4,024	9,351	4,699	5,424	5,288
Current Deferred & Refundable Income Taxes	387	426	524	207	285	364	663	731	1,426	1,859
Plant, Property, & Equipment, net	6,413	6,848	7,615	7,421	7,688	8,251	9,183	8,507	9,402	10,252
Plant, Property & Equipment, gross	6,413	6,848	7,615	7,421	7,688	8,251	9,183	8,507	9,402	10,252
Total Noncurrent Assets	37,636	42,416	42,589	37,639	38,126	17,987	27,549	65,383	66,663	67,956
Long-Term Investments	543	826	1,036	922	1,459	1,147	1,237	1,142	1,677	1,900
Noncurrent Note & Lease Receivables	907	901	847	515	740	720	895	835	803	930
Goodwill	11,800	11,658	11,825	11,707	11,668	11,845	19,997	19,820	20,048	21,025
Intangible Assets	22,646	27,586	26,188	21,959	20,833	-	-	39,307	38,089	37,177
Noncurrent Deferred & Refundable Income Taxes	1,294	1,102	2,189	2,379	2,718	3,438	4,330	3,263	4,718	5,347
Other Noncurrent Operating Assets	446	343	504	157	708	837	1,090	1,016	1,328	1,577
Total Liabilities & Shareholders' Equity	58,621	61,080	61,926	59,211	59,331	65,306	103,919	95,015	99,655	102,624
Total Liabilities	41,547	45,857	46,712	46,607	46,781	51,091	66,076	59,425	61,953	63,164
Total Current Liabilities	14,869	15,256	16,383	16,292	18,117	20,307	22,594	26,293	30,542	27,866
Short-Term Debt	916	2,307	2,247	1,754	1,822	2,194	1,660	5,314	5,129	2,337
Accounts Payable	11,663	10,486	11,641	12,841	13,987	15,785	18,938	19,040	22,374	22,465
Current Deferred & Payable Income Tax Liabilities	1,483	1,380	-	1,164	1,361	1,127	916	896	1,584	1,406
Other Current Liabilities	807	1,083	1,145	533	947	1,201	1,080	1,043	1,455	1,658
Total Noncurrent Liabilities	26,678	30,601	30,329	30,315	28,664	30,784	43,482	33,132	31,411	35,298
Long-Term Debt	14,137	14,501	15,560	17,359	15,730	17,507	28,134	22,965	22,365	26,506
Capital Lease Obligations	-	-	0.00	0.00	487	489	754	725	857	1,113
Noncurrent Deferred & Payable Income Tax Liabilities	2,665	3,956	3,995	3,286	2,490	2,918	6,206	2,944	2,844	3,543
Noncurrent Employee Benefit Liabilities	1,974	2,186	2,583	2,511	2,807	3,202	2,454	1,168	1,520	1,330
Other Noncurrent Operating Liabilities	7,902	9,958	8,191	7,159	7,150	6,668	5,934	5,330	3,825	2,806
Total Equity & Noncontrolling Interests	17,074	15,223	15,214	12,604	14,596	14,215	37,843	35,590	37,702	39,460
Total Preferred & Common Equity	36,999	31,523	31,602	26,512	11,081	31,260	78,555	74,095	78,309	81,657
Preferred Stock	4,304	4,351	4,393	4,427	-	7,971	35,126	35,155	35,188	35,226
Total Common Equity	12,751	9,057	9,139	6,601	13,127	6,228	2,698	414	2,491	4,149
Common Stock	316	316	317	317	328	328	387	387	388	388
Retained Earnings	11,834	8,140	8,221	5,683	2,812	5,299	1,710	-574	1,502	3,160
Other Equity Adjustments	601	601	601	601	7,941	601	601	601	601	601
Noncontrolling Interest	19	1,815	1,682	1,576	1,469	16	19	21	23	85

This table presents AstraZeneca's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q4 2023	Q4 2024
Total Assets	96,483	101,119	104,035
Total Current Assets	22,593	25,054	25,827
Cash & Equivalents	6,166	5,840	5,488
Short-Term Investments	326	238	220
Accounts Receivable	10,521	12,126	12,972
Inventories, net	4,699	5,424	5,288
Current Deferred & Refundable Income Taxes	731	1,426	1,859
Plant, Property, & Equipment, net	8,507	9,402	10,252
Plant, Property & Equipment, gross	8,507	9,402	10,252
Total Noncurrent Assets	65,383	66,663	67,956
Long-Term Investments	1,142	1,677	1,900
Noncurrent Note & Lease Receivables	835	803	930
Goodwill	19,820	20,048	21,025
Intangible Assets	39,307	38,089	37,177
Noncurrent Deferred & Refundable Income Taxes	3,263	4,718	5,347
Other Noncurrent Operating Assets	1,016	1,328	1,577
Total Liabilities & Shareholders' Equity	95,015	99,655	102,624
Total Liabilities	59,425	61,953	63,164
Total Current Liabilities	26,293	30,542	27,866
Short-Term Debt	5,314	5,129	2,337
Accounts Payable	19,040	22,374	22,465
Current Deferred & Payable Income Tax Liabilities	896	1,584	1,406
Other Current Liabilities	1,043	1,455	1,658
Total Noncurrent Liabilities	33,132	31,411	35,298
Long-Term Debt	22,965	22,365	26,506
Capital Lease Obligations	725	857	1,113
Noncurrent Deferred & Payable Income Tax Liabilities	2,944	2,844	3,543
Noncurrent Employee Benefit Liabilities	1,168	1,520	1,330
Other Noncurrent Operating Liabilities	5,330	3,825	2,806
Total Equity & Noncontrolling Interests	35,590	37,702	39,460
Total Preferred & Common Equity	74,095	78,309	81,657
Preferred Stock	35,155	35,188	35,226
Total Common Equity	414	2,491	4,149
Common Stock	387	388	388
Retained Earnings	-574	1,502	3,160
Other Equity Adjustments	601	601	601
Noncontrolling Interest	21	23	85

This table displays calculated financial ratios and metrics derived from AstraZeneca's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	-3.67%	-3.72%	-0.16%	-4.52%	39.16%	11.75%	32.35%	12.45%	13.30%
EBITDA Growth	0.00%	-14.67%	-5.36%	-66.53%	-30.18%	409.06%	-57.29%	131.78%	52.44%	10.37%
EBIT Growth	0.00%	4.59%	-5.36%	-66.53%	-30.18%	301.37%	-101.47%	5,449.13%	84.50%	6.02%
NOPAT Growth	0.00%	19.07%	-11.75%	-48.14%	-65.39%	438.86%	-89.01%	673.00%	75.99%	6.14%
Net Income Growth	0.00%	5.73%	0.60%	-68.10%	-70.76%	856.48%	-101.47%	5,449.13%	84.50%	6.02%
EPS Growth	0.00%	23.77%	-14.13%	-28.27%	-39.41%	136.89%	0.00%	0.00%	80.57%	18.11%
Operating Cash Flow Growth	0.00%	-19.73%	-13.68%	121.88%	-62.60%	129.61%	63.93%	34.74%	2.69%	19.65%
Free Cash Flow Firm Growth	0.00%	0.00%	-23.23%	-14.57%	-60.00%	761.46%	-139.77%	-121.64%	161.30%	-4.81%
Invested Capital Growth	0.00%	2.13%	7.89%	-8.79%	-5.23%	-77.53%	250.45%	196.96%	2.55%	5.78%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	72.74%	71.05%	70.94%	67.17%	79.82%	62.83%	65.88%	63.69%	66.53%	68.60%
EBITDA Margin	56.17%	49.76%	48.91%	16.40%	11.99%	43.87%	16.76%	29.36%	39.80%	38.77%
Operating Margin	45.44%	55.69%	48.03%	26.22%	11.99%	36.81%	5.17%	21.14%	33.09%	31.00%
EBIT Margin	45.83%	49.76%	48.91%	16.40%	11.99%	34.59%	-0.46%	18.44%	30.26%	28.31%
Profit (Net Income) Margin	44.83%	49.21%	51.42%	16.43%	5.03%	34.59%	-0.46%	18.44%	30.26%	28.31%
Tax Burden Percent	97.82%	98.90%	105.12%	100.00%	79.26%	100.00%	65.28%	100.00%	100.00%	100.00%
Interest Burden Percent	100.01%	100.01%	100.01%	100.19%	52.94%	100.00%	153.18%	100.00%	100.00%	100.00%
Effective Tax Rate	1.92%	1.10%	-5.12%	0.00%	20.74%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	46.97%	55.34%	46.49%	24.30%	9.05%	81.84%	10.88%	27.24%	31.64%	32.23%
ROIC Less NNEP Spread (ROIC-NNEP)	47.80%	40.19%	48.39%	5.98%	-0.03%	-6.18%	22.40%	-33.47%	24.49%	24.73%
Return on Net Nonoperating Assets (RNNOA)	25.45%	25.62%	39.93%	5.87%	-0.03%	-0.37%	-11.55%	-2.04%	14.95%	14.69%
Return on Equity (ROE)	72.42%	80.96%	86.43%	30.17%	9.02%	81.47%	-0.66%	25.20%	46.59%	46.92%
Cash Return on Invested Capital (CROIC)	0.00%	53.23%	38.90%	33.49%	14.42%	208.45%	-100.32%	-71.99%	29.13%	26.61%
Operating Return on Assets (OROA)	21.05%	21.57%	19.88%	6.75%	4.79%	18.32%	-0.20%	9.17%	17.28%	17.65%
Return on Assets (ROA)	20.59%	21.33%	20.90%	6.77%	2.01%	18.32%	-0.20%	9.17%	17.28%	17.65%
Return on Common Equity (ROCE)	54.08%	54.67%	51.67%	17.07%	6.54%	54.73%	-0.11%	1.07%	1.85%	4.04%
Return on Equity Simple (ROE_SIMPLE)	33.42%	41.47%	41.62%	15.83%	11.07%	37.54%	-0.22%	12.49%	21.80%	22.17%
Net Operating Profit after Tax (NOPAT)	12,290	14,634	12,914	6,697	2,318	12,489	1,373	10,611	18,674	19,821
NOPAT Margin	44.56%	55.08%	50.49%	26.22%	9.50%	36.81%	3.62%	21.14%	33.09%	31.00%
Net Nonoperating Expense Percent (NNEP)	-0.82%	15.15%	-1.90%	18.32%	9.08%	88.02%	-11.52%	60.72%	7.15%	7.50%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	16.43%	28.27%	28.55%
Cost of Revenue to Revenue	-4.42%	-10.53%	-2.81%	20.84%	20.18%	16.79%	33.99%	25.76%	15.61%	16.83%
SG&A Expenses to Revenue	40.29%	35.43%	40.01%	39.46%	47.91%	33.78%	38.52%	34.48%	34.77%	31.12%
R&D to Revenue	21.74%	22.17%	22.51%	23.23%	24.85%	17.66%	25.68%	19.45%	19.38%	21.24%
Operating Expenses to Revenue	58.98%	54.84%	54.78%	52.94%	72.76%	46.40%	60.71%	53.10%	51.30%	52.17%
Earnings before Interest and Taxes (EBIT)	12,639	13,219	12,511	4,188	2,924	11,736	-173	9,254	17,074	18,102
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	15,491	13,219	12,511	4,188	2,924	14,885	6,357	14,734	22,461	24,790
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	6.15	4.20	9.45	26.14	0.00	40.40	24.48
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	0.00	1.59	2.26	1.74	1.86	0.00	1.78	1.59
Price to Earnings (P/E)	0.00	0.00	0.00	10.19	26.79	5.06	0.00	0.00	5.89	5.61
Dividend Yield	5.58%	6.62%	4.97%	4.37%	3.22%	3.12%	2.61%	2.27%	2.23%	3.77%
Earnings Yield	0.00%	0.00%	0.00%	9.81%	3.73%	19.76%	0.00%	0.00%	16.98%	17.83%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	2.24	2.69	13.89	6.55	0.00	2.62	2.52
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	2.30	2.74	2.29	3.39	0.00	2.77	2.49
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	14.05	22.89	5.22	20.21	0.00	6.96	6.42
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	14.05	22.89	6.63	0.00	0.00	9.16	8.80
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	8.79	28.88	6.23	93.60	0.00	8.38	8.03
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	7.41	22.54	11.41	11.50	0.00	10.12	8.61
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	6.38	18.12	2.44	0.00	0.00	9.10	9.73
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.88	1.10	1.17	1.52	1.24	1.42	0.81	0.81	0.75	0.76
Long-Term Debt to Equity	0.83	0.95	1.02	1.38	1.11	1.27	0.76	0.67	0.62	0.70
Financial Leverage	0.53	0.64	0.83	0.98	0.88	0.06	-0.52	0.06	0.61	0.59
Leverage Ratio	3.52	3.80	4.14	4.46	4.49	4.45	3.31	2.75	2.70	2.66
Compound Leverage Factor	3.52	3.80	4.14	4.47	2.38	4.45	5.06	2.75	2.70	2.66
Debt to Total Capital	46.85%	52.47%	53.93%	60.26%	55.28%	58.68%	44.67%	44.90%	42.92%	43.15%
Short-Term Debt to Total Capital	2.85%	7.20%	6.80%	5.53%	5.58%	6.38%	2.43%	8.23%	7.77%	3.37%
Long-Term Debt to Total Capital	44.00%	45.27%	47.12%	54.73%	49.69%	52.31%	42.24%	36.68%	35.16%	39.79%
Preferred Equity to Total Capital	13.40%	13.58%	13.30%	13.96%	0.00%	23.17%	51.36%	54.42%	53.27%	50.75%
Noncontrolling Interests to Total Capital	0.06%	5.67%	5.09%	4.97%	4.50%	0.05%	0.03%	0.03%	0.03%	0.12%
Common Equity to Total Capital	39.69%	28.28%	27.68%	20.81%	40.22%	18.10%	3.95%	0.64%	3.77%	5.98%
Debt to EBITDA	0.97	1.27	1.42	4.56	6.17	1.36	4.81	1.97	1.26	1.21
Net Debt to EBITDA	0.49	0.76	0.97	2.93	3.53	0.73	3.59	1.45	0.92	0.90
Long-Term Debt to EBITDA	0.91	1.10	1.24	4.14	5.55	1.21	4.54	1.61	1.03	1.11
Debt to NOPAT	1.22	1.15	1.38	2.85	7.78	1.62	22.25	2.73	1.52	1.51
Net Debt to NOPAT	0.62	0.69	0.94	1.83	4.46	0.87	16.63	2.01	1.10	1.13
Long-Term Debt to NOPAT	1.15	0.99	1.20	2.59	7.00	1.44	21.04	2.23	1.24	1.39
Altman Z-Score	0.00	0.00	0.00	1.29	1.28	1.88	1.06	0.00	2.05	2.17
Noncontrolling Interest Sharing Ratio	25.32%	32.48%	40.22%	43.42%	27.47%	32.82%	82.85%	95.76%	96.04%	91.39%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.08	0.87	0.80	0.96	0.86	0.96	1.16	0.86	0.82	0.93
Quick Ratio	0.91	0.69	0.59	0.71	0.66	0.75	0.71	0.65	0.60	0.67
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	14,076	10,805	9,231	3,693	31,811	-12,652	-28,042	17,190	16,364
Operating Cash Flow to CapEx	0.00%	0.00%	2,222.36%	770.03%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	2.58	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	2.07	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	2.87	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.46	0.43	0.41	0.41	0.40	0.53	0.44	0.50	0.57	0.62
Accounts Receivable Turnover	4.16	4.75	5.34	4.83	4.30	5.31	4.55	4.98	4.98	5.10
Inventory Turnover	0.00	0.00	0.00	1.54	1.38	1.56	1.93	1.84	1.74	2.01
Fixed Asset Turnover	4.30	4.01	3.54	3.40	3.23	4.26	4.35	5.67	6.30	6.51
Accounts Payable Turnover	0.00	0.00	0.00	0.43	0.37	0.38	0.74	0.68	0.43	0.48
Days Sales Outstanding (DSO)	87.64	76.90	68.37	75.63	84.84	68.75	80.21	73.33	73.24	71.64
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	236.90	264.61	233.39	189.38	198.35	209.77	181.65
Days Payable Outstanding (DPO)	0.00	0.00	0.00	839.69	994.94	953.56	491.66	536.16	858.19	760.37
Cash Conversion Cycle (CCC)	87.64	76.90	68.37	-527.16	-645.50	-651.42	-222.06	-264.48	-575.18	-507.08
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	26,164	26,722	28,831	26,297	24,922	5,600	19,625	58,278	59,762	63,219
Invested Capital Turnover	1.05	1.00	0.92	0.93	0.95	2.22	3.01	1.29	0.96	1.04
Increase / (Decrease) in Invested Capital	0.00	558	2,109	-2,534	-1,375	-19,322	14,025	38,653	1,484	3,457
Enterprise Value (EV)	0.00	0.00	0.00	58,861	66,923	77,768	128,490	0.00	156,436	159,229
Market Capitalization	0.00	0.00	0.00	40,605	55,128	58,872	70,515	0.00	100,629	101,570
Book Value per Share	$10.09	$7.16	$7.22	$5.21	$10.36	$4.75	$2.06	$0.27	$1.61	$2.68
Tangible Book Value per Share	($17.16)	($23.86)	($22.81)	($21.37)	($15.29)	($4.28)	($13.18)	($37.93)	($35.90)	($34.87)
Total Capital	32,127	32,031	33,021	31,717	32,635	34,405	68,391	64,594	66,053	69,416
Total Debt	15,053	16,808	17,807	19,113	18,039	20,190	30,548	29,004	28,351	29,956
Total Long-Term Debt	14,137	14,501	15,560	17,359	16,217	17,996	28,888	23,690	23,222	27,619
Net Debt	7,655	10,053	12,189	12,253	10,326	10,909	22,830	21,370	20,596	22,348
Capital Expenditures (CapEx)	0.00	-63	161	1,031	-1,134	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-4,801	-5,616	-5,568	-4,885	-6,986	-6,703	-1,171	-4,878	-6,437	-5,410
Debt-free Net Working Capital (DFNWC)	2,054	313	-986	1,053	-732	1,431	5,310	1,614	-359	298
Net Working Capital (NWC)	1,138	-1,994	-3,233	-701	-2,554	-763	3,650	-3,700	-5,488	-2,039
Net Nonoperating Expense (NNE)	-75	1,560	-239	2,501	1,091	753	1,546	1,357	1,600	1,719
Net Nonoperating Obligations (NNO)	9,090	11,499	13,617	13,693	10,326	-8,615	-18,218	22,688	22,060	23,759
Total Depreciation and Amortization (D&A)	2,852	0.00	0.00	0.00	0.00	3,149	6,530	5,480	5,387	6,688
Debt-free, Cash-free Net Working Capital to Revenue	-17.41%	-21.14%	-21.77%	-19.13%	-28.65%	-19.75%	-3.09%	-9.72%	-11.41%	-8.46%
Debt-free Net Working Capital to Revenue	7.45%	1.18%	-3.85%	4.12%	-3.00%	4.22%	14.00%	3.22%	-0.64%	0.47%
Net Working Capital to Revenue	4.13%	-7.51%	-12.64%	-2.75%	-10.47%	-2.25%	9.63%	-7.37%	-9.73%	-3.19%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$2.37	$1.70	$1.03	$2.44	$0.00	$2.12	$3.84	$4.54
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	1.27B	1.27B	1.30B	1.31B	0.00	1.55B	1.55B	1.55B
Adjusted Diluted Earnings per Share	$0.00	$0.00	$2.37	$1.70	$1.03	$2.44	$0.00	$2.11	$3.81	$4.50
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	1.27B	1.27B	1.30B	1.31B	0.00	1.56B	1.56B	1.56B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	1.27B	1.27B	1.31B	1.31B	0.00	1.55B	1.55B	1.55B
Normalized Net Operating Profit after Tax (NOPAT)	12,290	14,634	8,600	4,688	2,318	8,742	1,373	7,428	13,072	13,875
Normalized NOPAT Margin	44.56%	55.08%	33.62%	18.36%	9.50%	25.76%	3.62%	14.80%	23.16%	21.70%
Pre Tax Income Margin	45.83%	49.76%	48.92%	16.43%	6.35%	34.59%	-0.70%	18.44%	30.26%	28.31%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	2.04	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	1.62	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	2.83	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	2.41	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	27.24%	26.75%	83.03%	292.75%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	27.24%	26.75%	83.03%	292.75%	0.00%	0.00%	0.00%	0.00%	0.00%

No quarterly metrics and ratios for AstraZeneca are available.

Frequently Asked Questions About AstraZeneca's Financials

When does AstraZeneca's fiscal year end?

According to the most recent income statement we have on file, AstraZeneca's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has AstraZeneca's net income changed over the last 9 years?

AstraZeneca's net income appears to be on an upward trend, with a most recent value of $18.10 billion in 2024, rising from $12.37 billion in 2015. The previous period was $17.07 billion in 2023.

What is AstraZeneca's operating income?

AstraZeneca's total operating income in 2024 was $19.82 billion, based on the following breakdown:

Total Gross Profit: $43.87 billion
Total Operating Expenses: $33.36 billion

How has AstraZeneca revenue changed over the last 9 years?

Over the last 9 years, AstraZeneca's total revenue changed from $27.58 billion in 2015 to $63.94 billion in 2024, a change of 131.8%.

How much debt does AstraZeneca have?

AstraZeneca's total liabilities were at $63.16 billion at the end of 2024, a 2.0% increase from 2023, and a 52.0% increase since 2015.

How much cash does AstraZeneca have?

In the past 9 years, AstraZeneca's cash and equivalents has ranged from $3.32 billion in 2017 to $7.83 billion in 2020, and is currently $5.49 billion as of their latest financial filing in 2024.

How has AstraZeneca's book value per share changed over the last 9 years?

Over the last 9 years, AstraZeneca's book value per share changed from 10.09 in 2015 to 2.68 in 2024, a change of -73.5%.

Remove Ads

Related Companies

This page (NASDAQ:AZN) was last updated on 4/13/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AstraZeneca (AZN) Financials

Frequently Asked Questions About AstraZeneca's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AstraZeneca (AZN) Financials

Annual Income Statements for AstraZeneca

Quarterly Income Statements for AstraZeneca

Annual Cash Flow Statements for AstraZeneca

Quarterly Cash Flow Statements for AstraZeneca

Annual Balance Sheets for AstraZeneca

Quarterly Balance Sheets for AstraZeneca

Annual Metrics and Ratios for AstraZeneca

Quarterly Metrics and Ratios for AstraZeneca

Frequently Asked Questions About AstraZeneca's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools